Lipocine (NASDAQ:LPCN) Stock Price Crosses Above Fifty Day Moving Average – Here’s What Happened

Lipocine Inc. (NASDAQ:LPCN) shares crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $2.31 and traded as high as $2.52. Lipocine shares last traded at $2.44, with a volume of 14,702 shares trading hands.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Weiss Ratings downgraded shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. HC Wainwright restated a “neutral” rating on shares of Lipocine in a research note on Monday, April 6th. Finally, Wall Street Zen lowered Lipocine from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $15.00.

Lipocine Stock Performance

The company has a market capitalization of $20.11 million, a PE ratio of -1.30 and a beta of 0.44. The company has a 50 day moving average price of $2.31 and a 200 day moving average price of $5.45.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.16 million. Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%. On average, equities analysts forecast that Lipocine Inc. will post -1.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lipocine

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of Lipocine by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after purchasing an additional 1,374 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in Lipocine in the fourth quarter valued at about $441,000. Renaissance Technologies LLC raised its stake in Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after buying an additional 1,300 shares in the last quarter. Jane Street Group LLC acquired a new stake in Lipocine during the fourth quarter valued at approximately $85,000. Finally, Citadel Advisors LLC bought a new position in Lipocine during the 3rd quarter worth approximately $41,000. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.